Hypogonadism is defined as hormonal disorder in which the glands (gonads & ovaries) produce little or no hormones causing its deficiency in the body. Hypogonadism in males refers to deficiency of testosterone due to dysfunction of either of the testes. Female hypogonadism refers to deficiency of estrogen or progesterone due to reduced activity of the ovaries. Hypogonadism is classified into two types: primary hypogonadism (testicular failure) and central hypogonadism (hypothalamic-pituitary axis dysfunction). Other major causes of hypogonadism include autoimmune disorder, genetic disorder, severe infections, and liver and kidney diseases. Generally, hormone and imaging tests are used to diagnose hypogonadism.

According to the Boston University School of Medicine, around 4 million to 5 million men in the U.S. were affected with hypogonadism in 2003. The incidence of hypogonadism in men aged between 40 years and 69 years in the country is around 481,000 new cases per year. According to the European Male Aging Study, the prevalence of late onset hypogonadism in men aged between 40 and 79 was 2.1% in 2016. Studies suggest that hypogonadism in adult men is often underdiagnosed and undertreated and only 5%. According to the Urology Care Foundation, hypogonadism is a chronic condition which would require lifelong treatment. The treatment for hypogonadism depends on the cause and concern about fertility and includes treatment such as hormone replacement therapy or assisted reproduction.

Men with heart disease, HIV, COPD, or renal disease have high prevalence of hypogonadism. Factors such as rising prevalence of type 2 diabetes and obesity further increase the incidence of hypogonadism. Growth of the global hypogonadism treatment market is attributed to rise in geriatric population, increase in infertility, and improved diagnosis. However, growing concerns about the potential side effects, availability of generic drugs, and preference for other natural hormonal boosters and supplements are likely to hamper the growth of the hypogonadism treatment market. Increasing awareness, awaiting approvals for new generation drugs in pipeline, and technological advancements present significant opportunities in the hypogonadism treatment market.

The primary treatment option for hypogonadism is hormone replacement therapy. Based on product type, the market has been classified into testosterone replacement therapy, estrogen therapy, and progesterone therapy. Testosterone replacement therapy is the fastest growing segment as hypogonadism is more prevalent in men. The segment is expected to hold major share of the global market during the forecast period.

In terms of mode of administration, the hypogonadism treatment market has been broadly classified into transdermal patch, topical gel, buccal tablets, implantable pellet, intramuscular injections, and oral tablets. Transdermal patch followed by topical gels are anticipated to be the fastest growing segments as these provide steady route of administration and are easily modifiable over a short period of time. The oral and buccal tablets segments are anticipated to experience sluggish growth during the forecast period due to high side effects and liver diseases.

Based on the distribution channel they are segmented into hospital pharmacies, retail pharmacies and others. The major market share for the hypogonadism treatment market is for the retail pharmacies segment and is anticipated to rule the market during the forecast period as continuous long term treatment is required for the hypogonadism patient.

In terms of region, the global hypogonadism treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the largest market for hypogonadism treatment, accounting for more than half of the market share due to the factors such as increased adoption of newer highly advanced products, rising awareness about hormonal disorder including various treatment options available, and advancing health care infrastructure. However, Asia Pacific is anticipated to be the fastest growing market during the forecast period due to increasing urbanization and rise in the patient population.

Key players in the global hypogonadism treatment market are Bayer AG, Abbott Laboratories, Inc., Merck Serono, Sanofi, Merck & Co., Inc., Actavis, Inc., AbbVie Inc., AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Endo International plc, Ferring Holding S.A., and Laboratoires Genevrier.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Hypogonadism Treatment Market

Pre Book